These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22383691)

  • 1. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
    QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent studies show promise for treating rare pancreatic tumors.
    Peres J
    J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA; Kleijn SA
    N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract]   [Full Text] [Related]  

  • 4. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 5. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
    [No Abstract]   [Full Text] [Related]  

  • 6. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J; Tabernero J
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME; Uomo I; Pastorello M
    JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
    [No Abstract]   [Full Text] [Related]  

  • 9. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
    Raymond E; Ruszniewski P
    Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
    Crippa S; Partelli S; Boninsegna L; Falconi M
    Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
    [No Abstract]   [Full Text] [Related]  

  • 13. Translational medicine: Cancer lessons from mice to humans.
    Tuveson D; Hanahan D
    Nature; 2011 Mar; 471(7338):316-7. PubMed ID: 21412332
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG; Strosberg JR; Halfdanarson TR
    Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
    Yim KL
    Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T; Roukos DH
    Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.